^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
Excerpt:
...Median Event Free Survival of AML patients with Flt3-ITD mutations`Median Event Free Survival of the patients in each of the four strata (Flt3 Non-ITD/NPM1 WT, Flt3 Non-ITD/NPM1 mut, Flt3 ITD/NPM1 WT, Flt3 ITD/NPM1 mut)`Median Overall Survival of AML patients with Flt3-ITD mutations`Median Overall Survival of all AML patients`Rate of Complete Remission in all AML patients`Rate of Molecular Remission in all AML patients`Toxicity`Evidence of Minimal Residual Disease in all AML patients`Development of Biomarkers indicating the course of disease...
Trial ID:
Source:
Title:
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
Published date:
02/18/2021
Excerpt:
A total number of 46/267 patients had FLT3-internal tandem duplication (ITD)-positive AML (17%) and 86/267 had NPM1-mutated AML (33%, Table 1)....The CR rate was 60% (81/134) in the sorafenib arm...In summary, the addition of sorafenib to standard intensive treatment led to a significant EFS and RFS prolongation after prolonged follow-up.
DOI:
10.1038/s41375-021-01148-x
Trial ID:
